Xintela AB (OSTO:XINT) Net Margin %: -2,659.14% (As of Mar. 2026)


OSTO:XINT Xintela AB OSTO:XINT
12 GF Score
Price kr0.18
! 2 Warning Signs
View Full Analysis

What is Xintela AB Net Margin %?

Xintela AB OSTO:XINT -6.25% 12 Net Margin % is -2,659.14% as of Mar. 2026. GuruFocus rates OSTO:XINT with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Xintela AB ranks worse than 83.74% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Xintela AB's Net Income for the three months ended in Mar. 2026 was kr-11.78 Mil. Xintela AB's Revenue for the three months ended in Mar. 2026 was kr0.44 Mil. Therefore, Xintela AB's net margin for the quarter that ended in Mar. 2026 was -2,659.14%.

The historical rank and industry rank for Xintela AB's Net Margin % or its related term are showing as below:

OSTO:XINT' s Net Margin % Range Over the Past 10 Years
Min: -1097250   Med: -69337.18   Max: -929.77
Current: -1931.03

OSTO:XINT's Net Margin % is ranked worse than
83.74% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs OSTO:XINT: -1931.03

Xintela AB  (OSTO:XINT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Xintela AB Net Margin % Related Terms

Xintela AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Xintela AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB Net Margin % Chart

Xintela AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -69,337.18 -929.77 -2,128.13

Xintela AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,447.86 -1,371.44 -1,109.82 -4,021.45 -2,659.14

OSTO:XINT vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Xintela AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xintela AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Xintela AB's Net Margin % falls into.


OSTO:XINT
12GF Score
Xintela AB OSTO:XINT
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Xintela AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-48.564/2.282
=-2,128.13 %

Xintela AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.78/0.443
=-2,659.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -2,659.14% mean?
Xintela AB (OSTO:XINT) has a Net Margin % of -2,659.14% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #793 out of 947 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Xintela AB's Net Margin % too high?
Xintela AB's current Net Margin % is -2,659.14%. Based on the distribution chart, Xintela AB ranks #793 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xintela AB has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #793 out of 947 companies for Net Margin %. This places Xintela AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Xintela AB and its competitors. Xintela AB's current Net Margin % is -2,659.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (OSTO:XINT) has a current Net Margin % of -2,659.14%. The current Net Margin % is -2,659.14%. Xintela AB's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Xintela AB (OSTO:XINT), the current Net Margin % is -2,659.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Other Exchanges 1XT:Germany
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
12GF Score

Get the complete analysis for OSTO:XINT

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price